CN105873941A - 生存素导向的癌症疫苗治疗 - Google Patents

生存素导向的癌症疫苗治疗 Download PDF

Info

Publication number
CN105873941A
CN105873941A CN201480068752.XA CN201480068752A CN105873941A CN 105873941 A CN105873941 A CN 105873941A CN 201480068752 A CN201480068752 A CN 201480068752A CN 105873941 A CN105873941 A CN 105873941A
Authority
CN
China
Prior art keywords
survivin
truncated
dotap
liposomal
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201480068752.XA
Other languages
English (en)
Chinese (zh)
Inventor
S·盖斯勒
P·伯尼福特
J·普拉什克
M·维冈特
S·杰克尔
R·凯尔纳
T·里斯奥克
D·穆勒-珀帕拉
K·汉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN105873941A publication Critical patent/CN105873941A/zh
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201480068752.XA 2013-12-16 2014-12-16 生存素导向的癌症疫苗治疗 Withdrawn CN105873941A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13005831 2013-12-16
EP13005831.6 2013-12-16
PCT/EP2014/003384 WO2015090572A1 (en) 2013-12-16 2014-12-16 Survivin-directed cancer vaccine therapy

Publications (1)

Publication Number Publication Date
CN105873941A true CN105873941A (zh) 2016-08-17

Family

ID=49884863

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480068752.XA Withdrawn CN105873941A (zh) 2013-12-16 2014-12-16 生存素导向的癌症疫苗治疗

Country Status (8)

Country Link
US (1) US20160279213A1 (enExample)
EP (1) EP3083663A1 (enExample)
JP (1) JP2017501172A (enExample)
CN (1) CN105873941A (enExample)
AU (1) AU2014365888B2 (enExample)
CA (1) CA2933705A1 (enExample)
IL (1) IL246299A0 (enExample)
WO (1) WO2015090572A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109125741A (zh) * 2018-08-13 2019-01-04 四川大学 透明质酸/dotap/生存素编码基因自组装的三元复合物制剂及其制备方法
CN116617414A (zh) * 2023-03-31 2023-08-22 中国农业大学 一种脂质体及其制备方法和应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
MX387323B (es) * 2014-02-19 2025-03-18 Merck Patent Gmbh Il-12 dirigida al cáncer en combinación con il-7 para usarse en el tratamiento de cáncer.
CN107951861B (zh) * 2016-10-17 2020-12-01 南京绿叶制药有限公司 一种脂质纳米粒膜材料组合物
KR102069680B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역억제인자 제어물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
CN109125740B (zh) * 2017-06-28 2022-04-05 成都威斯克生物医药有限公司 一种新型的肿瘤疫苗及其用途
CA3117914A1 (en) * 2018-10-24 2020-04-30 Apa- Advanced Technologies Ltd. Fusogenic liposomes for selective imaging of tumor cells
US20220125903A1 (en) * 2018-11-19 2022-04-28 Immunovaccine Technologies Inc. Methods for improving the efficacy of a survivin therapeutic in the treatment of tumors
CN111983240B (zh) * 2020-08-27 2023-11-21 天津大学 一种产气荚膜梭菌α毒素可视化检测的方法
JP7318983B2 (ja) * 2021-12-21 2023-08-01 株式会社アビー 細胞凍結保存液、及び細胞凍結方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022589A3 (en) * 1996-11-20 1998-10-29 Univ Yale Survivin, a protein that inhibits cellular apoptosis, and its modulation
CN1629311A (zh) * 2003-12-19 2005-06-22 叶尚勉 检测待测标本中生存素表达量的诊断试剂、检测方法及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2523172T3 (es) * 2005-02-04 2014-11-21 Survac Aps Vacuna de péptido de survivina
EP2276495B1 (en) * 2008-04-17 2018-11-21 PDS Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022589A3 (en) * 1996-11-20 1998-10-29 Univ Yale Survivin, a protein that inhibits cellular apoptosis, and its modulation
CN1629311A (zh) * 2003-12-19 2005-06-22 叶尚勉 检测待测标本中生存素表达量的诊断试剂、检测方法及应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHAOHONG SUN: "Solution Structure of Human Survivin and Its Binding Interface with Smac/Diablo", 《BIOCHEMISTRY》 *
DARIO C. ALTIERI: ""Targeted therapy by disabling crossroad signaling networks: the survivin paradigm"", 《MOL CANCER THER》 *
JUAN C. AON等: "Suppressing Posttranslational Gluconoylation of Heterologous Proteins by Metabolic Engineering of Escherichia coli", 《APPLIED AND ENVIRONMENTAL MICROBIOLOGY》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109125741A (zh) * 2018-08-13 2019-01-04 四川大学 透明质酸/dotap/生存素编码基因自组装的三元复合物制剂及其制备方法
CN109125741B (zh) * 2018-08-13 2022-02-11 四川大学 透明质酸/dotap/生存素编码基因自组装的三元复合物制剂及其制备方法
CN116617414A (zh) * 2023-03-31 2023-08-22 中国农业大学 一种脂质体及其制备方法和应用
CN116617414B (zh) * 2023-03-31 2024-04-05 中国农业大学 一种脂质体及其制备方法和应用

Also Published As

Publication number Publication date
WO2015090572A1 (en) 2015-06-25
JP2017501172A (ja) 2017-01-12
EP3083663A1 (en) 2016-10-26
AU2014365888A1 (en) 2016-07-28
AU2014365888B2 (en) 2018-12-06
CA2933705A1 (en) 2015-06-25
US20160279213A1 (en) 2016-09-29
IL246299A0 (en) 2016-07-31

Similar Documents

Publication Publication Date Title
AU2014365888B2 (en) Survivin-directed cancer vaccine therapy
US12220484B2 (en) Stable formulations of lipids and liposomes
JP6832904B2 (ja) 免疫療法のためのｒｎａ製剤
ES2702622T3 (es) Método para mejorar la eficacia de una vacuna de survivina en el tratamiento de cáncer
Wu et al. CASTING: A potent supramolecular strategy to cytosolically deliver STING agonist for cancer immunotherapy and SARS-CoV-2 vaccination
EP3140320B1 (en) Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
KR102823291B1 (ko) 종양-관련된 항원 에피토프의 미생물 서열 변이체
KR102375057B1 (ko) Hsp90 항원성 펩타이드를 포함하는 항암용 백신 조성물
CN105283199A (zh) 通过muc-1脂肽接种治疗肺癌的方法
US20250302975A1 (en) Methods and compositions for agonising tlr3
JP2012523847A (ja) Ｎｇｅｐ抗原の免疫原性エピトープ
HK40004722A (en) Rna formulation for immunotherapy
HK40004722B (en) Rna formulation for immunotherapy
HK1242215A1 (en) Stable formulations of lipids and liposomes
HK1242215B (zh) 脂质和脂质体的稳定制剂
HK1240829B (en) Stable formulations of lipids and liposomes
HK1240829A1 (en) Stable formulations of lipids and liposomes
HK1231899A1 (en) Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
HK1231899B (en) Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
HK1220914B (en) Method for improving the efficacy of a survivin vaccine in the treatment of cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20160817

WW01 Invention patent application withdrawn after publication